Decentralized diagnostics become workflow platforms, blood screening enters clinical care, and liquid biopsy turns decision support

Regulated Decentralized Diagnostics Are Becoming Workflow Platforms

Waters’ at-home HPV launch and SmartVertigo’s FDA submission show the same shift: decentralized diagnostics are moving from consumer-facing convenience to regulated, clinician-supervised workflows. Waters’ Onclarity HPV Self-Collection Kit uses the existing FDA-approved BD Onclarity HPV Assay and is being commercialized through partnerships, including Everlywell. SmartVertigo, under FDA submission K260566, is a prescription point-of-care vestibular system that combines a smartphone, light-occluding headset, and AI software to capture and classify nystagmus, suggest likely canal involvement, and recommend maneuver options while leaving diagnosis and treatment to the clinician.

Together with Tempus and BoneXpert’s FDA-cleared AI tools, these products point to a market where portability only matters when paired with formal clearance, workflow integration, and post-market evidence generation. The competitive edge is shifting away from standalone assay or device performance toward validated end-to-end clinical execution under tighter AI oversight. For operators and vendors, that raises the bar on monitoring and clinical integration; for investors, value is concentrating in platforms that can prove decentralized adoption without sacrificing regulatory-grade validation.

Blood-Based Cancer Screening Moves From Assay Novelty to Workflow Integration

FDA actions on Grail’s Galleri and Abbott’s SimpleScreen CRC show blood-based cancer screening moving from R&D promise into regulated clinical workflows. In the FDA advisory panel review of Galleri, the panel voted 7–2 with one abstention to recommend approval for adults 50 and older, but only with labeling that it is not a replacement for standard screening and should not be described as “early” detection. Panelists were split 6–4 on whether there was reasonable assurance of effectiveness, underscoring concerns about false positives, false reassurance, and the need for patient education and follow-up pathways.

Abbott’s SimpleScreen CRC is already FDA-approved for adults 45 and older at average risk, used after clinician referral, with a positive result indicating CRC or advanced precancerous lesions may be present and requiring colonoscopy follow-up. Approval was supported by PREEMPT CRC, a study of more than 48,000 participants, with reported sensitivity of 81.1% and specificity of 90.4%.

The competitive battleground is shifting from test performance alone to workflow integration, reimbursement readiness, and the ability to route positives into timely downstream care without undermining established screening programs.

Liquid Biopsy Moves from Panel Testing to Multi-Omics Decision Support

Caris Life Sciences this week launched an advanced Caris Assure, a multi-omics liquid biopsy for oncology patients with solid tumors, especially advanced, recurrent, or metastatic disease when tissue is limited, unavailable, or time-sensitive. From a single blood draw, the assay combines whole exome and whole transcriptome sequencing across plasma, white blood cells, and buffy coat to distinguish tumor-derived variants from clonal hematopoiesis and surface incidental germline findings.

Caris says the test spans more than 23,000 genes, reaches sequencing depth up to roughly 40,000x with about 600 million RNA reads, and reports MSI, TMB, LOH, HLA, and pharmacogenomic findings. The company cited validation across more than 3,000 samples, with sensitivity of 73% to 95.7% across stages I-IV and specificity around 99.5% to 99.6%.

The strategic shift is clear: liquid biopsy is moving beyond plasma-only, targeted mutation panels toward higher-content precision diagnostics that compete on interpretive depth and clinical utility. That raises the bar for vendors still anchored in narrow workflows, but commercial adoption will still hinge on reimbursement and real-world evidence, not analytical performance alone.